chemical

7680/10

7680/10

10 mg (also 50 mg)

159 USD

7680/10

ABT 263

10 mg (also 50 mg)

High affinity Bcl-2 family inhibitor; proapoptotic, senolytic and antitumor

Bcl-2 Family Inhibitors

Small Molecules

98%

974.62

?utm_source=labome&utm_medium=referral&utm_campaign=product&utm_term=smallmolecules

ABT 263 is a high affinity inhibitor of Bcl-2 family proteins (Ki values are 0.5 nM, 1 nM and 1 nM in Bcl-xL, Bcl-2 and Bcl-W respectively). ABT 263 induces G1/G0 phase arrest, apoptosis and autophagy in cancer cells in vitro (IC50 = 3.4 - 12 M). In vivo , ABT 263 displays a synergistic antitumor effect with rituximab and Bortezomib (Cat. No. 7282), Docetaxel (Cat. No. 4056) and Erlotinib (Cat. No. 7194), and inhibits growth of SCLC xenografts when combined with (+)-JQ1 (Cat. No. 4499). ABT 263 also reduces inflammation and viral-induced senescence in SARS-CoV-2 infection in vivo , and clears senescent cells and rejuvenates aging stem cells. Orally bioavailable.

High affinity Bcl-2 family inhibitor; proapoptotic, senolytic and antitumor

High affinity Bcl-2 family inhibitor; proapoptotic, senolytic and antitumor

4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl]propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl]sulfonyl]benzamide

C47H55ClF3N5O6S3

C47H55ClF3N5O6S3

923564-51-6

159 USD

High affinity Bcl-2 family inhibitor; proapoptotic, senolytic and antitumor

Store at -20░C